Poor Response to Direct-Acting Antiviral Therapy in HCV-Infected Elderly Population: A Real-Life Cohort Study Based on GeneXpert ^® Technology

Abstract

Aim: This study aimed to determine the efficacy of direct-acting antiviral drugs in different ethnicities and elderly population of Pakistan. Methods: We used GeneXpert® technology to quantify HCV RNA and evaluated treatment response in different cohorts that included HCV patients classified on the basis of their age-group and ethnicity. Results: The findings of our study suggest that 76% of nonresponder patients were older than 55 years of age which shows that age is the predictor of treatment outcome of direct-acting antiviral drugs. In addition to this, no differences were observed in overall efficacy by ethnicity. Conclusion: Treatment-regimen sofosbuvir+ribavirin has a limited effect on older patients; therefore, practitioners and healthcare professionals need to reconsider treatment options for elderly populations.

Risk of adverse outcomes following treatment with direct acting antiviral drugs in HCV infected patients with liver cirrhosis

“…Age-wise treatment response was not significantly different between both study-groups. In contrast to the findings of our study, Wahid B et al (2018) reported poor SVR among older age (>60 years) patients as compared to patients of less than 60 years [ 13 ].…”

Prevalence of thyroid stimulating hormone dysfunction among sofosbuvir‐treated HCV‐infected patients: A real‐world clinical experience

“…NS5A inhibitors include velpatasvir, elbasvir, ledipasvir, daclatasvir, and ombitasvir. IFN‐free DAA combinations have revolutionized the area of HCV therapeutics, and 95% of patients with CHC have been reported to achieve end treatment response in contrast to which we have observed increasing rate of late HCV relapse even after DAA drug therapy …”

Evaluation of Direct Acting Antiviral Agents in the Treatment of Patients With Chronic Hepatitis C Infection in Alexandria

“…In accordance, in Vallet et al, (2017) [27] and results revealed a very good response rate to DAAs (95%). In contrast, Wahid et al, (2018) [34] aimed to determine the efficacy of DAAs in elderly people. They found that most of non-responders were older than 55 years of age.…”